ACT is a proprietary formula that consists of microbubbles and microdroplets that are activated via ultrasound to increase the targeted delivery of a co-administered therapeutic agent. Preclinical data have shown that it enhances treatment for pancreatic, breast, colon, and prostate cancer, as well as managing blood-brain barrier opening.

The therapy is being evaluated in patients with metastatic colorectal and pancreatic cancer in a phase I trial at the Royal Marsden Hospital in London.